New Director of the National Cancer Institute Appointed

Publication
Article
OncologyONCOLOGY Vol 16 No 1
Volume 16
Issue 1

Andrew C. von Eschenbach, MD, has been named director of the National Cancer Institute (NCI) by President Bush. This appointment follows his recent selection as president-elect of the American Cancer Society.

Andrew C. von Eschenbach, MD, has beennamed director of the National Cancer Institute (NCI) by President Bush. Thisappointment follows his recent selection as president-elect of the AmericanCancer Society.

"Dr. von Eschenbach is one of the nation’s leaders in thebattle against cancer," said Health and Human Services Secretary Tommy G.Thompson. "I am confident that he will guide NCI to successes in thepursuit of discoveries in the biology, treatment, and prevention ofcancer."

Dr. von Eschenbach has spent most of his career at M. D.Anderson Cancer Center in Houston. After earning his medical degree fromGeorgetown University, he completed residencies in general surgery and urologyat the Pennsylvania Hospital in Philadelphia. He served a fellowship in urologiconcology at M. D. Anderson in 1976 and was invited to join the faculty thefollowing year.

Subsequently, Dr. von Eschenbach assumed many titles at M. D.Anderson. He was vice president of academic affairs and executive vice presidentand chief academic officer. In 1996, he was named founding director of M. D.Anderson’s Prostate Cancer Research Program, and in 1999, he became directorof the Genitourinary Cancer Center. He is also vice chairman of the SteeringCommittee for the National Dialogue on Cancer, and served for 3 years as firstchairman of the Prostate Cancer Research Program’s Integration Panel for theDepartment of Defense.

Dr. von Eschenbach says that while he is encouraged by recentprogress against many forms of cancer, he believes that accelerating basicresearch and applying laboratory findings more rapidly must be high priorities,to reduce the mortality and morbidity rates associated with all cancers.

Recent Videos
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Related Content